Cerebrolysin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins. It has been in clinical use in Europe and Asia since the 1970s and is approved in over 50 countries for the treatment of ischemic stroke, vascular dementia, Alzheimer's disease, and traumatic brain injury.
Its active fractions mimic the effects of endogenous neurotrophic factors including BDNF, NGF, CNTF, and GDNF, without being large enough to be classified as recombinant proteins. These peptide fractions cross the blood-brain barrier and promote neuronal survival, synaptic plasticity, and neurogenesis. Randomized controlled trials have demonstrated statistically significant improvements in neurological outcomes post-stroke and in Alzheimer's progression.
The Cochrane review on Cerebrolysin for dementia found positive effects on global clinical impression and cognitive function, though called for larger trials. It is commonly administered in 10-day IV cycles and is increasingly used off-label in high-performance cognitive protocols as an injectable alternative to conventional nootropics.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.